[ET Net News Agency, 2 February 2021] Daiwa Research lifted its target price for CSPC
Pharmaceutical (01093) to HK$7.5 from HK$6.8 and upgraded its rating to "hold" from
"sell", reflecting the potential benefits from its A-share dual-listing.
CSPC yesterday said it would pursue a STAR board A-share dual-listing. The research
house believes the company's shares will be traded at higher valuation multiples on the
A-share, and the dual-listing will open up new financing channels to support its long-term
development.
Daiwa expects NBP revenue to peak early in 2020 at CNY7.3bn, up 30%, and decline in
2021. Despite CSPC's efforts to penetrate lower-tier markets and expand to new
indications, Daiwa does not see NBP's sales volume growth doubling from the high base in
2020 to be enough to offset the 50% price cut. (KL)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01093 CSPC PHARMA
Nominal 
6.490 +0.270 (+4.341%) Research Report
02/02/2021 11:06
{I-bank focus}Daiwa lifts CSPC Pharma (01093) to HK$7.5
| Remark: | Real time quote last updated: 25/04/2024 13:13 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |